Axis Bank Ltd. Apr 11

  • ID: 1770773
  • April 2011
  • Standard & Poors
1 of 3

Sound funding profile Good income diversity Adequate capitalization Vulnerable asset quality The counterparty credit ratings on India-based Axis Bank Ltd. reflect the bank's sound funding profile, the significant and growing contribution of fee income to its operating revenues, and the bank's adequate capitalization. Axis' asset quality is adequate but vulnerable to deterioration because of a huge unseasoned portfolio and high credit concentration. The bank's adequate liquidity supports the rating. Axis' strong retail franchise stems from its brand equity. Its multiple delivery channels such as branches, ATMs, and the internet have led to a high contribution of savings and current deposits to aggregate funding. These inherently low-cost and stable deposits have constituted more than 40% of the bank's deposits for the...

Companies mentioned in this report are:
- Axis Bank Ltd.

Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Axis Bank Ltd.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.